Etifelmine
This is an old revision of this page, as edited by 88.106.30.20 (talk) at 08:28, 18 November 2022. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H19N |
Molar mass | 237.346 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Etifelmine (INN; also known as gilutensin) is a stimulant drug. It was used for the treatment of hypotension (low blood pressure).[1]
Synthesis
![](http://upload.wikimedia.org/wikipedia/commons/thumb/1/1d/Etifelmine_synthesis.svg/500px-Etifelmine_synthesis.svg.png)
The base catalyzed reaction between benzophenone [119-61-9] (1) and butyronitrile [109-74-0] (2) gives 2-[hydroxy(diphenyl)methyl]butanenitrile [22101-20-8] (3). Catalytic hydrogenation reduces the nitrile group to a primary amine giving 1,1-diphenyl-2-ethyl-3-aminopropanol [22101-87-7] (4). The tertiary hydroxyl group is dehydrated by treatment with anhydrous hydrogen chloride gas, completing the synthesis of Etifelmine (5).
See also
References
- ^ Poepelmann H (August 1964). "The treatment of hypotensive circulatory disorders with gilutensin". Therapie der Gegenwart (in German). 103: 1007–12. PMID 14254672.
- ^ Dr Werner Heinrich & Dr Walter Heigel, DE 1122514 (1962 to Giulini Gmbh Geb).
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |